Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection-Reference-Cited by-同舟云学术

Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection

Published:2023-12-22 Issue:52 Volume:120 Page:
ISSN:0027-8424
Container-title:Proceedings of the National Academy of Sciences
language:en
Short-container-title:Proc. Natl. Acad. Sci. U.S.A.

Author:

Miyamoto Sho¹,Nishiyama Takara²^ORCID,Ueno Akira¹^ORCID,Park Hyeongki²,Kanno Takayuki¹^ORCID,Nakamura Naotoshi²^ORCID,Ozono Seiya¹,Aihara Kazuyuki³^ORCID,Takahashi Kenichiro⁴,Tsuchihashi Yuuki⁵⁶^ORCID,Ishikane Masahiro⁷,Arashiro Takeshi¹⁵^ORCID,Saito Shinji¹,Ainai Akira¹^ORCID,Hirata Yuichiro¹,Iida Shun¹^ORCID,Katano Harutaka¹^ORCID,Tobiume Minoru¹,Tokunaga Kenzo¹^ORCID,Fujimoto Tsuguto⁴^ORCID,Suzuki Michiyo⁷,Nagashima Maki⁷,Nakagawa Hidenori⁸,Narita Masashi⁹,Kato Yasuyuki¹⁰,Igari Hidetoshi¹¹^ORCID,Fujita Kaori¹²^ORCID,Kato Tatsuo¹³,Hiyama Kazutoshi¹⁴,Shindou Keisuke¹⁵,Adachi Takuya¹⁶^ORCID,Fukushima Kazuaki¹⁷^ORCID,Nakamura-Uchiyama Fukumi¹⁸,Hase Ryota¹⁹,Yoshimura Yukihiro²⁰^ORCID,Yamato Masaya²¹,Nozaki Yasuhiro²²,Ohmagari Norio⁷,Suzuki Motoi⁵,Saito Tomoya⁴,Iwami Shingo²²³²⁴²⁵²⁶^ORCID,Suzuki Tadaki¹^ORCID

Affiliation:

1. Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan

2. Interdisciplinary Biology Laboratory, Division of Natural Science, Graduate School of Science, Nagoya University, Aichi 464-8602, Japan

3. International Research Center for Neurointelligence, The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Tokyo 113-0033, Japan

4. Center for Emergency Preparedness and Response, National Institute of Infectious Diseases, Tokyo 162-8640, Japan

5. Center for surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo 162-8640, Japan

6. Center for Field Epidemic Intelligence, Research and Professional Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan

7. Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo 162-8655, Japan

8. Department of Infectious Diseases, Osaka City General Hospital, Osaka 534-0021, Japan

9. Division of Infectious Diseases, Department of Internal Medicine, Okinawa Prefectural Nanbu Medical Center and Children’s Medical Center, Okinawa 901-1193, Japan

10. Department of Infectious Diseases, International University of Health and Welfare Narita Hospital, Chiba 286-0124, Japan

11. Department of Infection Control, Chiba University Hospital, Chiba, Japan

12. Department of Respiratory Medicine, National Hospital Organization Okinawa National Hospital, Okinawa 901-2214, Japan

13. Department of Chest Disease, National Hospital Organization Nagara Medical Center, Gifu 502-8558, Japan

14. Department of Infectious Disease, National Hospital Organization Fukuoka-Higashi Medical Center, Fukuoka 811-3195, Japan

15. Department of Pediatrics, Hirakata City Hospital, Osaka 573-1013, Japan

16. Department of Infectious Diseases, Tokyo Metropolitan Toshima Hospital, Tokyo 173-0015, Japan

17. Department of Infectious Disease, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo 113-8677, Japan

18. Department of Infectious Diseases, Tokyo Metropolitan Bokutoh Hospital, Tokyo 130-8575, Japan

19. Department of Infectious Diseases, Japanese Red Cross Narita Hospital, Chiba 286-8523, Japan

20. Division of Infectious Disease, Yokohama Municipal Citizen’s Hospital, Kanagawa 221-0855, Japan

21. Department of General Internal Medicine and Infectious Diseases, Rinku General Medical Center 598-8577, Osaka, Japan

22. Department of Respiratory Medicine, Tokoname City Hospital, Aichi 479-8510, Japan

23. Institute of Mathematics for Industry, Kyushu University, Fukuoka 819-0395, Japan

24. Institute for the Advanced Study of Human Biology, Kyoto University, Kyoto 606-8501, Japan

25. Interdisciplinary Theoretical and Mathematical Sciences Program, RIKEN, Saitama 351-0198, Japan

26. NEXT-Ganken Program, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan

Abstract

Infectious virus shedding from individuals infected with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is used to estimate human-to-human transmission risk. Control of SARS-CoV-2 transmission requires identifying the immune correlates that protect infectious virus shedding. Mucosal immunity prevents infection by SARS-CoV-2, which replicates in the respiratory epithelium and spreads rapidly to other hosts. However, whether mucosal immunity prevents the shedding of the infectious virus in SARS-CoV-2-infected individuals is unknown. We examined the relationship between viral RNA shedding dynamics, duration of infectious virus shedding, and mucosal antibody responses during SARS-CoV-2 infection. Anti-spike secretory IgA antibodies (S-IgA) reduced viral RNA load and infectivity more than anti-spike IgG/IgA antibodies in infected nasopharyngeal samples. Compared with the IgG/IgA response, the anti-spike S-IgA post-infection responses affected the viral RNA shedding dynamics and predicted the duration of infectious virus shedding regardless of the immune history. These findings highlight the importance of anti-spike S-IgA responses in individuals infected with SARS-CoV-2 for preventing infectious virus shedding and SARS-CoV-2 transmission. Developing medical countermeasures to shorten S-IgA response time may help control human-to-human transmission of SARS-CoV-2 infection and prevent future respiratory virus pandemics.

Funder

MEXT | Japan Society for the Promotion of Science

Japan Agency for Medical Research and Development

Ministry of Health, Labour and Welfare

MEXT | Japan Science and Technology Agency

Secom Science and Technology Foundation

Suzuken Memorial Foundation

Life Science Foundation of Japan

Japan Prize Foundation

Foundation of Kinoshita Memorial Enterprise

Publisher

Proceedings of the National Academy of Sciences